Clal Insurance’s iShares Biotechnology ETF IBB Stock Holding History

Clal Insurance’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-315,776	Closed	-$35.3M	–	114
2019 Q1	$35.3M	Sell	315,776 -422,758	-57%	-$46.4M	0.86%	37
2018 Q4	$71.2M	Hold	738,534	–	–	1.85%	17
2018 Q3	$90.1M	Hold	738,534	–	–	2.39%	13
2018 Q2	$81.2M	Hold	738,534	–	–	2.11%	13
2018 Q1	$78.8M	Sell	738,534 -1,169,091	-61%	-$130M	2.1%	15
2017 Q4	$204M	Hold	1,907,625	–	–	5.36%	4
2017 Q3	$212M	Buy	1,907,625 +1,215,273	+176%	+$130M	5.12%	5
2017 Q2	$71.6M	Buy	692,352 +23,340	+3%	+$2.3M	1.42%	16
2017 Q1	$65.4M	Sell	669,012 -29,088	-4%	-$2.78M	1.33%	16
2016 Q4	$61.8M	Buy	698,100 +11,160	+2%	+$1.02M	1.16%	16
2016 Q3	$66.3M	Buy	+686,940	New	+$65.4M	1.49%	11
2015 Q1	–	Sell	-197,247	Closed	-$19.9M	–	126
2014 Q4	$19.9M	Buy	+197,247	New	+$19.2M	0.48%	50

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Clal Insurance's IBB Position: Q2 2019 in Review

Clal Insurance sold out of iShares Biotechnology ETF (IBB) in Q2 2019, closing a stake of 315,776 shares — an estimated $35.3M sold.

Clal Insurance first reported a position in IBB in Q4 2014 and held it in 12 quarters. The position peaked at $212M in Q3 2017. 646 funds tracked by Wall St. Rank hold IBB as of Q2 2019.

Clal Insurance reported no remaining iShares Biotechnology ETF position as of Q2 2019 after selling out during the quarter.
Clal Insurance sold 315,776 iShares Biotechnology ETF shares in Q2 2019, an estimated $35.3M.
Clal Insurance first reported a position in iShares Biotechnology ETF in Q4 2014 and held it in 12 quarters.
Clal Insurance's iShares Biotechnology ETF position peaked at $212M in Q3 2017.
646 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2019.

Based on Clal Insurance's 13F filing for Q2 2019, filed 13 Aug 2019.